Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0172

Payer / HTA meeting · Dr. Katarina Rossi

18 Aug 2026 · Virtual · Dr. Katarina Rossi, Charité Berlin · MSL James Whitfield · Lumeva

ReviewedVeeva CRMENG-0172MI request

Capture insight from this engagement

Location: Charité Berlin
Therapeutic area: Neurology
Country: Germany
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Lumeva (lumevarin)

Topics discussed

Dosing in hepatic impairment

Scientific content used

CGRP class review

Questions raised

What is the persistence rate at 18 months in real-world cohorts?

Notes

Payer / HTA meeting with general neurologist at Charité Berlin. Discussed dosing in hepatic impairment.

Insights captured (1)

Capture insight

INS-0056High
Dosing in hepatic impairment
Dosing in hepatic impairment: request for data reported by general neurologist (DE).
Action created

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 2
Depth of exchange: 2
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0172

Audit history (0)

All create, update and approval events for this record

No audit events in sample data